Fig. 6.

TNFα- and IFNγ-activated PI3K-AKT is required for the therapeutic effect of hUC-MSCs on IBD. a, e Bodyweight change of IBD mice treated with hUC-MSCs. The hUC-MSCs were pretreated with TNFα and IFNγ (10 ng/ml each) for 24 h. To block the glycolysis or OXPHOS, The hUC-MSCs were treated with 2-Deoxy-D-glucose (2-DG) or oligomycin (OM). b, f The IL-6 protein levels in the mouse serum were analyzed by ELISA. c, g The colon length of IBD mice treated with hUC-MSCs. The right panel shows the statistic analysis of the colon length of IBD mice. d, h The representative H&E stained colon sections of IBD mice treated with the hUC-MSCs and their histological scores. Scale bar, 200 μm. Data are presented as mean ± SEM. **, p < 0.01, ***, p < 0.001. n = 5 for each groups